As of 28/09/2023
Fund Overview
The Medical Cannabis and Wellness UCITS ETF is Europe’s first medical cannabis ETF .*
The CBDX medical cannabis ETF seeks to provide targeted exposure to the rapidly expanding legal medical cannabis industry that is set for further growth as more countries legalise cannabis for medical use. The fund tracks a rules-based Medical Cannabis and Wellness Equity Index from Solactive, consisting of publicly listed companies conducting legal business activities across nine thematic sub-sectors in the medical cannabis, hemp and CBD industries.
Please remember that the value of your investment may go down as well as up and past performance is no indication
of future performance.
*According
to HANetf research using ETF Database
Want to keep updated about
CBDX
and our other products?
Subscribe for updates
Why Invest in CBDX Medical Cannabis ETF?
A growing treatment for illnesses and diseases:
Medical cannabis can be used in the treatment of many of the world’s most pressing health concerns in cannabis including cancer, Alzheimer’s disease, glaucoma, epilepsy and chronic pain. New research and increasing legalisation of cannabis use for medical purposes is creating more demand for pharmaceutical grade cannabis and related services.
Global growth of medical cannabis use:
With the full legalization of cannabis in Canada and regulatory reform in the US, more countries are adopting a legalization framework for use of medical cannabis. As medical cannabis becomes more accepted, analysts expect the rate of cannabis reform to accelerate on a global scale.
Targeted, legal, exposure to the medical cannabis industry:
CBDX provides targeted exposure to a new and growing industry of companies engaged in the production and associated services and products in the medical cannabis industry. The fund has no explicit inclusion of big pharma companies in the index methodology to keep it focused on high exposure to the medical cannabis, hemp and CBD industry. Multiple levels of screening and oversight ensure companies in the index meet required laws, exchange listing rules and liquidity thresholds.
Risks
The Sub-Fund and the companies in which it invests may be subject to
a higher degree of regulatory oversight and regulatory action, which
may include a restriction on the types of companies that the Sub-Fund
may invest in at any time
If a company becomes delisted from an exchange due to
noncompliance with the rules and policies of the exchange, the
Investment Manager will use reasonable endeavours to remove the
company from the Sub-Fund's portfolio
The value of equities and equity-related securities can be affected by
daily stock and currency market movements
Investors' capital is fully at risk and investors may not get back the
amount originally invested
Exchange rate fluctuations could have a negative or positive effect on
returns
6. Further risks are disclosed in the KIID and Prospectus